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Background: The morbidity associated with severe uncontrolled asthma is disproportionately higher in low- and
middle-income countries than in high-income countries. The aim of this study was to describe the phenotypic
characteristics of difficult-to-treat severe asthma and treatment-resistant severe asthma in a sample of children
and adolescents in Brazil.
Methods: This was a prospective study, conducted between 2010 and 2014, following 61 patients (6–18 years of
age) who had been diagnosed with severe uncontrolled asthma. The patients were classified and managed in
accordance with the World Health Organization asthma follow-up protocol, which calls for re-evaluations of the
diagnosis, level of control (functional and clinical), comorbidities, inhaler technique, and environmental factors,
together with adjustment of the treatment to achieve a target level of control. We assessed pulmonary function,
measured fractional exhaled nitric oxide, and performed sputum cytology. After the target rate of≥ 80% adherence to
inhaled corticosteroid treatment had been reached and all of the re-evaluations had been performed, the patients
incorrectly diagnosed with severe uncontrolled asthma were excluded and the remaining patients were classified as
having treatment-resistant or difficult-to-treat severe asthma.
Results: We found that, of the 61 patients evaluated, 10 had been misdiagnosed (i.e., they did not have asthma),
15 had moderate asthma, and 36 had severe uncontrolled asthma. Among those 36 patients, the asthma was
classified as treatment-resistant in 20 (55.6%) and as difficult-to-treat in 16 (44.4%). In comparison with the
patients with difficult-to-treat severe asthma, those with treatment-resistant severe asthma showed a higher
median level of fractional exhaled nitric oxide (40 ppb vs. 12 ppb; P < 0.037) and a lower median forced expiratory
volume in one second (61% vs. 87%; P < 0.001).
Conclusions: Although patients with treatment-resistant severe asthma cannot always be distinguished from
those with difficult-to-treat severe asthma on the basis of baseline clinical characteristics, reduced airflow and
elevated fractional exhaled nitric oxide are factors that could distinguish the two groups. Patients diagnosed with
severe uncontrolled asthma should be re-evaluated on a regular basis, in order to exclude other diagnoses, to
reduce exacerbations, and to identify patients with persistent airflow limitation.
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Severe uncontrolled asthma comprises three categories [1]:
untreated severe asthma; difficult-to-treat severe asthma;
and treatment-resistant severe asthma. Those categories
differ in terms of their connotation in the context of public
health, as well as in terms of the challenges they pose.
Failure to achieve and maintain asthma control can
increase the risk and frequency of exacerbations, as well as
increasing the risk of asthma-related death. Individuals
with uncontrolled asthma are also more likely to have ad-
verse reactions to asthma medications and to develop
chronic morbidity, such as impaired pulmonary function.
In children with uncontrolled asthma, lung growth can
also be impaired [1].
Patients with severe uncontrolled asthma should be
evaluated carefully. The evaluation of such patients
should include the differential diagnosis of their symp-
toms, the determination of their access to medications,
and the identification of potentially reversible risk fac-
tors (comorbidities, inefficient inhaler technique, poor
adherence to the treatment regimen, and asthma triggers
in the environment). In addition, attempts should be
made to determine whether the use of maintenance
medications is optimal [1-3]. The objective of such evalua-
tions is to distinguish patients with treatment-resistant se-
vere asthma, in whom the symptoms remain uncontrolled
despite the highest level of recommended treatment or
control can be maintained only with the highest level of
recommended treatment, from those with difficult-to-
treat severe asthma, in whom control can be achieved
after the removal of reversible risk factors [1]. It is import-
ant to make the distinction between treatment-resistant
severe asthma and difficult-to-treat severe asthma, in
order to avoid unnecessary invasive procedures, minimize
adverse effects of asthma medications, and hold down
health care costs, given that asthma control is possible in
patients with difficult-to-treat severe asthma, whereas
those with treatment-resistant severe asthma are candi-
dates for clinical trials of other treatment strategies [1,3].
There have been few studies aimed at distinguishing
between difficult-to-treat severe asthma and treatment-
resistant severe asthma in children and adolescents.
Studies conducted in high-income countries have re-
ported inconsistent findings [4,5]. Some authors have
suggested that patients with difficult-to-treat severe
asthma show better baseline pulmonary function and
lower fractional exhaled nitric oxide (FeNO) than do those
with treatment-resistant severe asthma [4]. In contrast,
others have found that neither FeNO nor forced expira-
tory volume in one second (FEV1) discriminate between
those two phenotypes of severe uncontrolled asthma [5].
According to data from the International Study of
Asthma and Allergies in Childhood [6], the prevalence
of asthma among 13- to 14-year-olds in Brazil isapproximately 20%. The morbidity associated with se-
vere uncontrolled asthma is disproportionately higher in
low- and middle-income countries (LMICs) than in
high-income countries [1,7], which calls attention to the
need for studies aimed at identifying strategies for redu-
cing asthma-related morbidity in LMICs. A group of ex-
perts assembled by the World Health Organization
(WHO) has proposed a protocol for severe asthma
follow-up and intervention, which defines three categor-
ies of severe uncontrolled asthma [1]. The objective of
the present study was to describe the phenotypes of
severe uncontrolled asthma in a sample of children and
adolescents in Brazil.
Methods
This was a prospective study conducted between June
2010 and May 2014 at a referral center for severe
asthma, the Multidisciplinary Center for Difficult-to-
Control Asthma of the Federal University of Minas Gerais
Hospital das Clínicas located in the city of Belo Horizonte,
in southeastern Brazil. The center, which operates under
the auspices of the Belo Horizonte Municipal “Wheezy
Child” Program [8], serves an area in which most families
are of low socioeconomic status, providing them with
asthma medications and spacers for inhalers, all at no cost
to the families. Children and adolescents with asthma are
referred from primary care physicians to pediatric pulmo-
nologists, who in turn refer them to our facility. Conse-
quently, the patients evaluated in this study all suffered
from asthma that could not be controlled in primary or
secondary care. We defined a diagnosis of severe uncon-
trolled asthma as described by the WHO [1]: “Uncontrolled
asthma which can result in risk of frequent severe exacer-
bations (or death) and/or adverse reactions to medications
and/or chronic morbidity (including impaired lung function
or reduced lung growth in children)”.
Severe exacerbations were defined as those that re-
quired the use of systemic corticosteroids, unscheduled
visits to the emergency room, or emergency hospital
admissions [1].
 The categories, or phenotypes, of severe
uncontrolled asthma were defined as follows [1-3]:
untreated severe asthma—asthma for which the
treatment is not appropriate to the degree of severity
 difficult-to-treat severe asthma—asthma in which a
lack of control or partial control is attributed to
other factors (lack of access to asthma medications,
poor adherence to treatment, incorrect inhaler
technique, exposure to tobacco smoke, exposure to
allergens in the environment, and psychosocial
stressors)
 treatment-resistant severe asthma—asthma that is
uncontrolled or only partially controlled despite the
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in combination with a long-acting β2 agonist
(LABA), with or without the regular or constant use
of systemic corticosteroids, or asthma that can be
controlled only with such aggressive treatment
Patients
We included all 6- to 18-year-old patients referred to
our facility with a suspected diagnosis of severe uncon-
trolled asthma. Those patients were re-evaluated once
every three months at our facility.
Assessments
The patients were evaluated in accordance with the
severe asthma follow-up protocol proposed by the
WHO consultants, which is designed to characterize
the phenotypes of severe uncontrolled asthma [1]. To
distinguish between treatment-resistant severe asthma
and difficult-to-treat severe asthma [1,2], the WHO
protocol includes the following: re-evaluation of the
level of asthma control; re-evaluation of the diagnosis;
re-evaluation of the factors associated with a lack of
control (comorbidities, lack of treatment adherence,
incorrect inhaler technique, and environmental factors);
and adjustment of the treatment to a level appropriate to
the level of control.
Evaluation of the level of asthma control
We evaluated the level of asthma control in accordance
with the criteria established by the Global Initiative for
Asthma [9], utilizing the following parameters: daytime
symptoms; nighttime symptoms; ability to perform phys-
ical activities; occurrence of exacerbations; the need for
rescue medication; and the FEV1. We also applied the
Asthma Control Test (ACT), on which a score < 20 (out
of a maximum of 25) indicates a lack of control [10].
Functional control of asthma was evaluated by spirom-
etry (Spirobank® II; MIR, Rome, Italy), in accordance
with the recommendations of the American Thoracic
Society [11]. Before and after the administration of a
bronchodilator (400 μg of albuterol) by pressurized
metered-dose inhaler (pMDI), we measured FEV1, forced
vital capacity (FVC), the FEV1/FVC ratio, and forced ex-
piratory flow between 25% and 75% of the vital capacity
(FEF25–75%). A post-bronchodilator increase in FEV1 of
200 ml or ≥ 12% was considered significant [12]. All pa-
rameters are expressed as a percentage of the predicted
value, based on age, gender, and height [12,13].
Confirmation of the diagnosis of the asthma
Patients in whom asthma control was not achieved
after their comorbidities had been evaluated and their
treatment regimen had been adjusted were submitted
to clinical assessment in order to rule out alternativediagnoses [1-3]. When clinically indicated (in 66.7% of
the patients), we performed high-resolution computed
tomography scans of the chest, with slices during in-
spiration and expiration. We also determined chloride
concentrations in sweat (in all of the patients); monitored
esophageal pH (in 38.9%); administered tuberculin skin
tests (in all of the patients); conducted immunological
testing, determining immunoglobulin levels (in all of
the patients), immunophenotyping lymphocytes (in
11.1%), and quantifying the response to vaccine anti-
gens (in all of the patients); and performed bronchos-
copy (in 8.3%). In one case, we studied the morphology
of the cilia under electron microscopy. When indicated,
we also performed cardiological, otorhinolaryngological,
and psychiatric evaluations (in 44.4%, 38.9%, and 8.3% of
the patients, respectively) [1-3].
Evaluation of associated factors
Allergic rhinitis and allergic sensitization Diagnoses
of persistent allergic rhinitis were re-evaluated in ac-
cordance with the criteria of the Allergic Rhinitis and its
Impact on Asthma initiative [14], which classify allergic
rhinitis as persistent or intermittent, as well as grading it
as mild, moderate, or severe. Those determinations are
made on the basis of one or more of the six signs and
symptoms of allergic rhinitis (oropharyngeal pruritus,
sneezing, watery rhinorrhea, nasal pruritus, ocular prur-
itus, and nasal obstruction) being present for four or
more days in a week and for more than four consecutive
weeks [14]. We also employed an adapted clinical scale
for rhinitis [15], which has previously been used in Brazil
[16]. Each of the six parameters (nasal pruritus, oropha-
ryngeal pruritus, ocular pruritus, rhinorrhea, sneezing,
and nasal obstruction) is scored from 0 (better) to 3
(worse), the maximum possible score therefore being 18.
Allergic sensitization was defined as positivity on a
skin prick test (ALK-Abelló, Hørsholm, Denmark). Test
results were considered positive when the papule size
was 3 mm greater than was that of the negative control.
The following allergens were tested: Dermatophagoides
pteronyssinus, Dermatophagoides farinae, Blomia tropicalis,
Alternaria alternata, Aspergillus fumigatus, cat dander,
dog dander, and cockroach allergens (from Periplaneta
americana and Blattella germanica). The positive and
negative controls were histamine and saline solution,
respectively [17].
We determined serum levels of total immunoglobulin
E with a fluorescence enzyme immunoassay (ImmunoCAP;
Phadia, Uppsala, Sweden), using the reference values based
on age range [18].
Inhaler technique Patient inhaler technique was evalu-
ated on the basis of the recommendations for the proper
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reviewed at every visit. The pMDIs were used with a
spacer attached to the mouthpiece [19].
Psychosocial and emotional factors Patients with anx-
iety or depressive disorders were identified as outlined in
the Global Initiative for Asthma [9]. Those so identified
were evaluated and treated by a psychiatrist.
Gastroesophageal reflux disease Patients with gastro-
esophageal reflux disease, as evidenced by epigastric
pain or heartburn, underwent 24-h pH monitoring and,
if necessary, upper gastrointestinal endoscopy [10].
Adherence to treatment The rate of adherence to treat-
ment with an ICS was obtained by calculating what per-
centage of the total number of recommended doses
during a given period were taken by the patient. To that
end, we consulted the dose counters of the inhalers,
counted the empty DPI capsules, and checked those
counts against the records of the dates on which the
medications were dispensed [1,8,20].
Evaluation of the environment
We classified the home environment as uncontrolled
when the parents or guardians reported the presence of
mold, dust mites, pets, or smoking in the home [2,9].
Measures aimed at reducing exposure (using washable
covers on mattresses, dusting furniture with a damp
cloth, keeping pets outside, and prohibiting smoking
within the home) were recommended as necessary [21].
Evaluation of sputum cellularity
We induced sputum with an ultrasonic nebulizer (Devilbiss
Healthcare, Langen, Germany), in accordance with the rec-
ommendations of the European Respiratory Society [22].
Patients with clinical signs and symptoms of infection were
exempted from sputum induction. In patients with
stable asthma who showed post-bronchodilator values
of FEV1 ≥ 60% of predicted, we used 4.5% hypertonic sa-
line, whereas we used normal saline in those who
showed post-bronchodilator values of FEV1 < 60%. The
processing of the induced sputum samples was also per-
formed in accordance with the recommendations of the
European Respiratory Society. Samples were considered
usable if they contained ≤ 20% squamous cells, showed ≥
50% cell viability, and had ≥ 400 inflammatory cells [22,23].
The pattern of cellularity was defined as follows [22,23]:
eosinophilic (when eosinophils accounted for ≥ 2.5% and
neutrophils accounted for ≤ 54%); neutrophilic (when eo-
sinophils accounted for < 2.5% and neutrophils accounted
for > 54%); or paucicellular (when eosinophils accounted
for < 2.5% and neutrophils accounted for < 54%).Measurement of FeNO
In all cases, FeNO was measured prior to the spirometry
and when the patient was free of upper airway infections.
Using a portable analyzer (NIOX MINO; Aerocrine AB,
Solna, Sweden), we obtained the FeNO values at an expira-
tory flow rate of 50 ml/s [24].
Optimizing the treatment
We optimized the treatment in accordance with the level
of control [7]. The patients were using DPIs delivering a
combination of budesonide and formoterol, either Sym-
bicort (AstraZeneca, Lund, Sweden) or Alenia (Aché
Laboratórios Farmacêuticos S.A., Guarulhos, Brazil); or
DPIs or pMDIs containing fluticasone combined with
salmeterol (Seretide; GlaxoSmithKline, Stevenage, UK),
montelucaste (Montelair; Aché Laboratórios), oral pred-
nisolone (generic), or omalizumab (Xolair; Novartis Bio-
ciências S.A., São Paulo, Brazil).
Statistical analysis
Before and after the interventions recommended by the
WHO consultants, we performed comparative analyses
using McNemar’s test and the Wilcoxon test. In our ana-
lysis, we included only those patients who were ≥ 80%
adherent to the treatment regimen, dividing them into
two groups on the basis of whether or not clinical and
functional control of the asthma was achieved [1-3]:
difficult-to-treat severe asthma (in which such control was
achieved); and treatment-resistant severe asthma (in which
it was not). We then evaluated the groups in terms of the
baseline characteristics that might differentiate between
the two, using the chi-square test (with Yates’ correction
or Fisher’s exact test), or the Mann–Whitney test, as ne-
cessary. The level of statistical significance was set at 5%.
Ethical aspects
The study was approved by the Federal University of
Minas Gerais Research Ethics Committee (Protocol no.
149/10). All participating patients or their legal guardians
gave written informed consent.
Results
We found that 10 (16.4%) of the 61 patients evaluated
had been misdiagnosed (i.e., they did not have asthma),
15 (24.6%) had moderate asthma, and 36 (59.0%) had se-
vere uncontrolled asthma. The alternative diagnoses in-
cluded bronchiolitis obliterans following an infection (in
six patients), cystic fibrosis (in one), primary ciliary dys-
kinesia (in one), pulmonary tuberculosis (in one), and a
sequela of bronchopulmonary dysplasia (in one). Those
36 patients comprised our study sample. Table 1 shows
the baseline demographic, anthropometric, and clinical
characteristics of the patients.
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was high, with a median of five exacerbations in the last
12 months. All of the patients had uncontrolled asthma
and were taking high doses of ICS, which is characteristic
of severe uncontrolled asthma. Despite the lack of control,
25% of the patients were being treated with regimens that
did not include a LABA and were therefore classified as
receiving treatment that was not appropriate to the level
of control. The majority of the patients had severe persist-
ent allergic rhinitis and were exposed to dust mite aller-
gens and tobacco smoke in their environment. In addition,
36% used incorrect inhaler techniques, the most common
errors being not exhaling completely before inhaling the
medication and not inhaling deeply enough. Table 2 showsTable 1 Baseline characteristics of pediatric patients with
severe uncontrolled asthma (N = 36) treated at a referral
center for asthma in Brazil
Variable n (%) Median (IQR)
Female gender 23
(63.9)
Age (years) 11.6 (6.2 to 17.8)
Height (Z score) 0.05 (−2.66 to
1.00)
BMI (Z score) −0.48 (−2.90 to
1.84)
Well-controlled home environment 9 (25.0)
Severe persistent allergic rhinitis 35
(97.2)
Severe exacerbations in the last 12 months 5 (1 to 20)
Allergic rhinitis score 8 (0 to 18)
Gastroesophageal reflux disease 7 (19.4)
Psychiatric disorder 3 (8.3)




Fully adherent to treatment 2 (5.6)
Previous pulmonary function testing 16
(44.4)
Incorrect inhaler technique 13 (36)
Previous ICU admission 7 (19.5)
Uncontrolled asthma (GINA criteria) 36
(100)
Posology and medications in use
Equivalent dose of budesonide (μg) 800 (800 to 1200)
ICS alone 9 (25.0)
ICS + LABA 27
(75.0)
Leukotriene receptor antagonists 4 (11.1)
Continuous oral ICS 3 (8.3)
Omalizumab 0 (0.0)
IQR: interquartile range; BMI: body mass index; ICU: intensive care unit; GINA:
Global Initiative for Asthma.the characteristics of the patients before and after the
interventions recommended by the WHO consultants [1].
After the interventions, there was an increase in the pro-
portion of patients showing correct inhaler technique, to-
gether with better rhinitis scores, better ACT scores, and
an increase in the use of leukotriene receptor antagonists.
In addition, there were post-intervention reductions in the
number of exacerbations, in the FeNO levels, and in the
post-bronchodilator variations in FEV1 and FEF25–75%, as
well as an increase in the absolute values for FEV1.
Table 3 shows the comparative analysis between the
patients with treatment-resistant severe asthma and
those with difficult-to-treat severe asthma. At baseline,
FEV1 was 61% and 87% of the predicted value in the pa-
tients with treatment-resistant severe asthma and
difficult-to-treat severe asthma, respectively, and the
pre-bronchodilator values of FEV1, FEV1/FVC ratio, and
FEF25–75% were lower in the patients with treatment-
resistant severe asthma than in those with difficult-to-
treat severe asthma, as were the post-bronchodilator
variations in FEV1 and FEF25–75%. After the interven-
tions, 20 (55.6%) of the 36 patients were classified as
having treatment-resistant severe asthma and 16 (44.4%)
were classified as having difficult-to-treat severe asthma.
We found that the two phenotypes were indistinguish-
able on the basis of baseline clinical characteristics or
atopy, although a distinction between the two was sug-
gested on the basis of the baseline spirometry results
and level of FeNO. In the sample as a whole, the median
time to achieving ≥ 80% adherence to treatment was six
months, and there was no statistical difference between
the two groups in terms of that parameter.
Discussion
We found that 16.4% of the patients referred with a
diagnosis of severe uncontrolled asthma did not have
asthma at all. This finding is in agreement with those of
other studies, in which 12–50% of such patients were
found to have been misdiagnosed [25]. This underscores
the importance of re-evaluating the diagnosis of asthma
in patients who do not achieve control [1,9].
At baseline, the majority of our patients were under
treatment with high doses of ICS and LABA, which is a
reflection of the fact that those medications are made read-
ily available by the health care system in the area served by
our referral center. A consensus statement recently pub-
lished jointly by the European Respiratory Society and the
American Thoracic Society provided age-specific guidelines
for the appropriate doses of inhaled corticosteroid in cases
of “severe therapy-resistant asthma” [26]. The median age
of our patients was 11.6 years (range, 6.2–17.8 years). our
patients who were ≤ 12 years of age were treated with a
daily dose of 800 μg of inhaled budesonide or equivalent,
which the aforementioned guidelines classify as a high dose
Table 2 Characteristics of pediatric patients with severe uncontrolled asthma (N = 36) before and after application of
the WHO protocola,b
Variable Pre-protocol Post-protocol P
Correct inhaler technique 23 (63.9) 31 (86.1) 0.008
Fully adherent to treatment 2 (5.6) 34 (94.4) N/A
Rhinitis score 8 (0–18) 5 (0–15) 0.001
Asthma Control Test score 16.5 (6–25) 22.5 (8–25) 0.002
Posology and medications in use
Leukotriene receptor antagonists 4 (11.1) 12 (33.3) 0.008
Omalizumab 0 (0) 1 (2.7) N/A
Continuous oral ICS 3 (8.3) 8 (22.2) 0.063
Equivalent dose of budesonide (μg) 800 (800–1200) 800 (800–1600) 0.059
Well-controlled home environment 9 (25) 15 (41.7) 0.109
Psychiatric disorder 3 (8.3) 8 (22.2) 0.125
Number of exacerbations 4 (0–20) 2 (0–11) 0.006
Sputum cytologyc
Eosinophils (%) 2.0 (0–37) 1.1 (0–49) 0.948
Eosinophils≥ 2.5% 9 (25.0) 9 (25.0) 0.362
Neutrophils > 54% 4 (17.4) 6 (18.8) 0.114
Pre-BD FEV1 (%) 77.0 (36–113) 78.7 (31–113) 0.038
Pre-BD FEV1/FVC ratio (%) 78.0 (53–100) 80.0 (43–95) 0.417
Pre-BD FE 25–75% (%) 61.0 (16–131) 66.5 (15–110) 0.156
Post-BD variation in FEV1 (%) 11.0 (0–70) 5.0 (0–45) 0.004
Post-BD variation in FEF25–75% (%) 31.0 (0.0–166.0) 14.0 (0.0–96.0) 0.013
FeNO (ppb) 31 (5–125) 14 (0–112) 0.016
aValues expressed as n (%) or as median (range); bmedian time between the pre- and post-protocol evaluations: 6.07 months (range, 0.7–24.27 months); csome
patients were unable to produce usable sputum samples: 13 in the pre-protocol evaluation; and 4 in the post-protocol evaluation. BD: bronchodilator.
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were referred from health care systems in which
LABAs are not made available accounted for the fact
that 25% of the patients were not receiving treatment
appropriate to the severity of their asthma. In addition,
other asthma medications, such as leukotriene receptor
antagonists and omalizumab, were unavailable to those
patients. It is important that all effective asthma medi-
cations are made available and accessible to asthma pa-
tients, which is not always the case in LMICs [1,2]. In
Brazil, a study designed to estimate the direct and
indirect costs of severe asthma, as well as the overall
economic impact of asthma, conducted under the aus-
pices of the Bahia State Program for the Control of
Asthma and Allergic Rhinitis, showed that the costs of
asthma treatment consume, on average, 24% of the
total family income in the city of Salvador (capital of
the state of Bahia) [27]. When the indirect costs were
included, that figure rose to 29%. The participants in
the present study had free access to appropriate medi-
cations via the public health care system.
It is of note that, at baseline, asthma was uncontrolled in
all of the patients, even those for whom high doses of ICSand LABA had been prescribed. In the majority of cases,
there was no documentation of the medication having been
dispensed and the patients did not have their inhalers with
them, which precluded the counting of the doses. There-
fore, prescribing a given medication does not guarantee that
it will be administered.
One of the major factors associated with a lack of asthma
control is poor adherence to treatment. Despite the fact
that there are no fully reliable methods of verifying such ad-
herence, it is recommended that it be quantified with one
of the methods available, given that the definition of severe
uncontrolled asthma is based on of the dosage required to
effectively achieve and maintain control of the symptoms
[1,20]. Within the health care systems that provide asthma
medications, dispensing records could play an important
role by allowing patients who do not refill their prescrip-
tions to be identified. Thus, pharmacists could be on the
front lines of the battle to improve treatment adherence,
which is particularly important in patients with severe
asthma. Because poor adherence to treatment is one of the
major determinants of severe uncontrolled asthma, we
opted to evaluate the patients in our sample only after they
had reached a rate of adherence ≥ 80%.
Table 3 Baseline characteristics of pediatric patients with severe uncontrolled asthma (N = 36) treated at a referral
center for asthma in Brazil, by phenotypea
Variable Severe uncontrolled asthma P
Treatment-resistant asthma Difficult-to-treat asthma
(n = 20) (n = 16)
Female gender 13 (65.0) 10 (62.5) 0.846
Age (years) 12.0 (6.4–17.8) 11.0 (6.2–17.7) 0.514
Pattern of sputum cellularityb
Eosinophilic 5 (31.3) 1 (14.3) 0.52
Neutrophilic 3 (18.8) 1 (14.3)
Paucicellulara 6 (37.5) 4 (57.1)
Mixed 2 (12.5) 1 (14.3)
Number of ICU admissions 0.0 (0.0–6.0) 0.0 (0.0–4.0) 0.621
Courses of oral corticosteroids in the last 12 months (n) 0.5 (0.0–7.0) 1.00 (0.0–12.0) 0.143
Exacerbations in the last 12 months 6 (1–12.0) 4 (1–20.0) 0.311
Time to achieve≥ 80% adherence and complete the protocol (months) 6.2 (0.7–24.2) 5.8 (1.4–17.3) 0.987
Asthma Control Test score 14 (6–24) 18 (10–24) 0.091
Rhinitis score 7.5 (4–15) 9 (0–15) 0.886
FVC (% of predicted) 74.9 (59.6–106.7) 93.6 (81.3–117) <0.001
FEV1 (% of predicted) 61.0 (36.0–98.6) 87.0 (72.1–113) <0.001
FEV1/FVC ratio 78.3 (43.1–86.1) 84.3 (72.1–98.9) 0.009
FEF25–75% (%of predicted) 39.8 (16.0–83.1) 74.6 (29.1–131.3) 0.002
Post-BD variation in FEV1 (%) 17.0 (1.7–70.0) 6.2 (0.0–38.3) 0.012
Post-BD variation in FEF25–75% (%) 38.9 (1.4–166.0) 24.6 (0.0–59.2) 0.031
Equivalent dose of budesonide (μg) 800 (800–1200) 800 (800–800) 0.975
FeNO (ppb) 40 (7–125) 12 (5–53) 0.037
Total IgE total (mg/dl) 1040 (65–3000) 454 (11–2500) 0.098
Sensitization to dust mite allergens 20 (100) 12 (80) 0.069
Sensitization to fungi 7 (35) 5 (33.3) 0.603
Sensitization to pet dander 5 (25) 4 (26.7) 0.605
Sensitization to cockroach allergens 4 (20) 3 (20) 0.659
aValues expressed as n (%) or as median (range); bsome patients were unable to produce usable sputum samples: 4 in the treatment-resistant group; and 9 in the
difficult-to-treat group. ICU: intensive care unit; BD: bronchodilator; IgE: immunoglobulin E.
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of adherence to treatment. In our sample, the median
time required to reach ≥ 80% adherence was six months.
We found it surprising that it took so long for our patients
to achieve a satisfactory rate of adherence, especially be-
cause they were already receiving appropriate treatment,
which made it impossible to increase the dosages or add
other recommended medications during that period.
Sharples et al. reported that 41% of patients with
treatment-resistant severe asthma were ≥ 80% adherent
to treatment, compared with only 24% of those with
difficult-to-treat severe asthma [4]. In the present study,
we distinguished between the two phenotypes only
after ≥ 80% adherence had been achieved. The authors of
an earlier study of asthma treatment in children and ad-
olescents concluded that the rate of adherence reportedby parents or guardians is higher than is the true (mea-
sured) rate [28]. In a study of children with treatment-
resistant severe asthma [5], another group of authors
used the reported rates of adherence but questioned
the reliability of those data, suggesting that some
method of quantifying adherence should be employed,
which would allow poorly adherent individuals to be
identified.
Despite the prerequisite of a documented ≥ 80% rate of
adherence, 55.6% of our patients did not achieve clinical
or functional asthma control. This finding is consistent
with those of Sharples et al., who reported that, among
the patients with uncontrolled asthma, the rate of adher-
ence was 60.3% in those with treatment-resistant severe
asthma, compared with 39.7% in those with difficult-to-
treat severe asthma [4].
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panel of experts, we were able to increase the rate of ad-
herence, improve ACT scores, increase the proportion of
patients using correct inhaler techniques, improve rhinitis
scores, optimize the treatment regimens, and maximize
the environmental control, which is considered essential.
Although it is not always easy or simple to achieve, it is
important that these essential measures are taken. In
the present study, we found that the interventions ap-
plied resulted in a satisfactory level of environmental
control, despite the fact that we were able to eliminate
smoking from the home environment (as determined
on the basis of self-reported smoking cessation on the
part of the residents) in only six of the cases, in which
family members who reported smoking in the home
had been referred to the smoking cessation outpatient
clinic of a university hospital for treatment. It is pos-
sible that the environment could have been controlled
more efficiently had home visits occurred [21].
Differentiating between treatment-resistant severe
asthma and difficult-to-treat severe asthma has important
implications for clinical practice. Patients with treatment-
resistant severe asthma cannot achieve a satisfactory level
of control even when potential risk factors are removed,
such patients being candidates for clinical trials of new
treatment strategies. In patients with treatment-resistant
severe asthma, evaluations that are more invasive can be
justified [29]. In patients with difficult-to-treat severe
asthma, however, control can be achieved when the essen-
tial measures are taken, resulting in fewer exacerbations,
social reintegration of the patients, and a reduction in
health care costs.
In the present study, it was not possible to distinguish
between the patients with treatment-resistant severe
asthma and those with difficult-to-treat severe asthma
on the basis of their baseline clinical characteristics (in-
cluding ACT and rhinitis scores) or clinical history
(number of exacerbations and number of admissions to
the intensive care unit). That might explain, in part, the
high morbidity that both groups of patients exhibited at
baseline. It is possible to distinguish between the two
phenotypes only after the essential measures have been
taken, which is difficult to achieve outside of a special-
ized treatment facility. However, we identified markers
that are suggestive of a distinction between treatment-
resistant and difficult-to-treat severe asthma prior to any
intervention, such markers including spirometry values
and the FeNO level.
We found statistically significant baseline differences
between the patients with treatment-resistant severe
asthma and those with difficult-to-treat severe asthma in
terms of the pre-bronchodilator FEV1, FEV1/FVC ratio,
and FEF25–75%, as well as the post-bronchodilator varia-
tions in FEV1 and FEF25–75%. Sharples et al. observedsuch a difference, although only for post-bronchodilator
variations in FEV1, whereas Konradsen et al. found no
difference in FEV1 values between the two phenotypes
[5]. The latter group of authors reported that the paren-
tal level of education and family income were both lower
among the patients with treatment-resistant severe
asthma [5]. In the present study, all of the patients
belonged to families with monthly incomes below US$
600.00 and only one patient had a parent with more
than a high school education.
In our sample, the median FeNO values at baseline
were higher in the patients with treatment-resistant se-
vere asthma than in those with difficult-to-treat severe
asthma (40 ppb vs. 12 ppb). Sharples et al. also showed
that FeNO discriminates between the two phenotypes
[4], although Konradsen et al. found no such distinction
[5]. Despite the statistical significance observed in the
present study, the viability of monitoring FeNO in LMICs
has to be questioned. Although the determination of FeNO
is a non-invasive procedure that is easily performed, it is
too costly to be incorporated into the routine evaluation of
all patients suspected of having severe asthma.
In another study evaluating induced sputum samples
collected from children and adolescents, Bossley et al.
reported that the median proportion of eosinophils was
7.5% in the atopic patients with treatment-resistant severe
asthma, among whom the median age was 11.8 years of age
[30]. In a study comparing controlled severe asthma with
mild asthma in children and adolescents, no significant dif-
ferences were found between the two types in terms of the
proportion of eosinophils in induced sputum [31]. In the
present study, we also found no significant difference be-
tween treatment-resistant severe asthma and difficult-to-
treat severe asthma in terms of the pattern of cellularity in
sputum. Nevertheless, it is notable that sputum eosinophilia
persisted in 25% of our patients even after the treatment
regimen had been optimized.
In a study of sputum induction in children with diffi-
cult asthma, Lex et al. found that 11% had sputum neu-
trophilia [23]. The authors pointed out that, although
all of the children evaluated were chronically symptom-
atic, only a minority had sputum neutrophilia or eosino-
philia. One possible explanation proposed by the authors
is that the high doses of corticosteroids used in treating
those children might have altered the sputum cytology
[23]. In the present study, we identified sputum neutrophi-
lia in 18.8% of the treatment-resistant severe asthma group
patients who were able to produce usable sputum samples
in the post-protocol evaluation, none of whom had shown
any clinical signs or symptoms of respiratory tract infec-
tion. It is possible that this was also a side effect of treat-
ment, given that our patients were using high doses of
inhaled corticosteroids, which have been shown to inhibit
neutrophil apoptosis [32].
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important to the evaluation of asthma control [1,9]. In
our sample as a whole, 44.4% of the patients had never
undergone pulmonary function testing. They presented
with baseline values of 77% and 78% for FEV1 and the
FEV1/FVC ratio, respectively, which are indicative of
mild obstructive lung disease, as would be expected. In
some studies, FEV1 has been reported to be only slightly
altered in children with severe uncontrolled asthma [3]. In
the present study, baseline FEV1 was comparable between
the patients with treatment-resistant severe asthma and
those with difficult-to-treat severe asthma. Therefore, it was
possible to distinguish between the two phenotypes only by
evaluating pulmonary function in detail. Even at the end of
the follow-up period (after the WHO protocol had been ap-
plied and a high rate of adherence to treatment had been
achieved), pulmonary function was still abnormal in 55.6%
of our patients. That might be attributable to airway re-
modeling. It is possible that this population of patients
could benefit from treatment with medications that have
yet to be standardized for use in pediatric patients. It is also
possible that, in LMICs, there is a large contingent of indi-
viduals with severe asthma featuring persistent airway limi-
tation. Studies investigating this issue are warranted. There
is also a need for studies evaluating the medium- and long-
term risks of persistent airway limitation in children and
adolescents in LMICs. A study conducted in high-income
countries showed that children with severe asthma are at
increased risk of developing adult COPD in adulthood,
even if they never become smokers. The fixed abnormal-
ities in lung function in adult life are established in early
childhood and track at lower values progressing to persist-
ent airway limitation in adulthood [33].
Evaluating 45 atopic pediatric patients with treatment-
resistant severe asthma, Bossley et al. observed thickening
of the basement membrane and of the smooth muscle
layer, indicating airway remodeling [30]. In those same
patients, the authors found that the mean baseline
FEV1 was 66% of the predicted value, comparable to the
61% observed in our sample. The authors suggested that
there is a real need for new therapeutic strategies targeting
children and adolescents with asthma that cannot be con-
trolled even with high doses of inhaled or oral corticoste-
roids [34], having also noted that the strategies employed
in adult asthma patients cannot necessarily be extrapo-
lated to children and adolescents [30]. Konradsen et al.
reported mean baseline FEV1 values of 86% and 76% in
their patients with treatment-resistant and difficult-to-
treat severe asthma, respectively [5].
Some authors have identified a statistically significant
difference between treatment-resistant and difficult-to-
treat severe asthma in terms of allergic sensitization to
aeroallergens, which was found to be more common in
pediatric patients with the treatment-resistant form [4].In the present study, we found no such distinction. In
our sample as a whole, all but two of the patients tested
positive for allergic sensitization. One of the patients in
our treatment-resistant severe asthma group tested posi-
tive for sensitivity to Aspergillus fumigatus. Twelve pa-
tients (five in our difficult-to-treat severe asthma group
and seven in our treatment-resistant severe asthma group)
tested positive for sensitivity to Alternaria alternata, al-
though computed scans of the chest revealed no bronchiec-
tasis in any of those patients. Fungal sensitization has been
associated with greater asthma severity [35].
One of the limitations of our study is that the sample
was highly selected, given that it comprised patients seen
at a referral center for severe asthma. However, the patients
had been referred from secondary health care facilities and
required an approach that involved asthma treatment at all
levels of health care.
Conclusions
Although patients seen at a referral center for severe
asthma constitute a relatively homogeneous group,
higher FeNO levels and greater impairment of pulmon-
ary function at baseline are suggestive of treatment-
resistant severe asthma. In our sample of children and
adolescents with severe uncontrolled asthma in Brazil,
we found that the evaluations and interventions pro-
posed by the WHO consultants were effective. After the
WHO protocol had been applied, we observed fewer ex-
acerbations, better symptom scores, a higher proportion
of patients using the correct inhaler technique, and
higher rates of adherence to treatment. The use of the
WHO protocol allowed us to exclude other diagnoses
and to demonstrate that, despite appropriate treatment,
many of the patients continued to show functional
impairment.
To address the disproportionately high rates of morbidity
associated with severe uncontrolled asthma in LMICs, we
need to do more than simply increase the availability of
asthma medications. In patients with severe uncontrolled
asthma, we need to monitor adherence to treatment and
the level of asthma control on a regular basis, which can
best be achieved at a referral center with asthma specialists
on staff. For certain patients, new treatment strategies need
to be developed.
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